Georgia becomes first recipient of free treatment through an innovative drug donation partnership between USAID and Janssen Therapeutics, a pharmaceutical company of Johnson & Johnson (Janssen)
"This partnership between USAID and Janssen is a significant step forward in the global fight against the threat of MDR-TB. I am confident that this will be a public-private partnership in which we can all be proud. By acting together to combat TB now, we can reduce the potential of drug-resistant TB in the future."- U.S. Ambassador to Georgia, Ian Kelly, speaking at the event in Tbilisi, Georgia, October 13, to mark the launch of the bedaquiline donation program in the country.
Patients in Georgia suffering from deadly strains of multidrug-resistant tuberculosis (MDR-TB) will soon have access to potentially life-saving medication thanks to a collaboration between the U.S. Agency for International Development (USAID) and Janssen. MDR-TB is a form of TB that is resistant to at least two of the four most commonly used anti-TB medicines.
Georgia is classified as a high MDR-TB burden country with 48 percent of known TB cases identified as multidrug-resistant. Nearly 200 patients in Georgia will begin receiving the tuberculosis drug, SIRTURO® (bedaquiline), as part of their treatment program for MDR-TB. Bedaquiline is the first new drug to treat TB in more than 40 years and can bring new hope to patients fighting MDR-TB with little to no other treatment options.
In Georgia, USAID-funded programs focus on improving early detection of TB, strengthening TB and MDR-TB control through technical assistance and capacity building, and supporting research and innovation.
Learn More
- Read more about the bedaquiline event in Georgia and view photos
- Read USAID's bedaquiline information webpage
- Learn more about TB in Georgia
- Explore the U.S. Government Global TB Strategy
- Discover USAID's work on antimicrobial resistance
- Find out more about Georgia
No hay comentarios:
Publicar un comentario